The Biobetters Market is expected to be worth US$ 99,000.0 Million at a CAGR of 8% between 2029. Healthcare is going the “digital” way. In other words, artificial intelligence (AI)-enabled medical devices and telemedicine are the concrete instances of the proliferation of the digital wave in the healthcare industry. This factor would be the one traversing the healthcare vertical in the forecast period.
Increasing usage of therapeutically more effective drugs for the treatment of chronic diseases is expected to drive the growth of biobetters market. Higher efficacy and lower adverse effects are among the important factors that are expected to fuel the growth of the biobetters market over the forecast period.
According to the latest research by the company, the global biobetters market is projected to account for a market value of around US$ 99,000.0 Mn by the end of 2029. The report also projects a significant growth potential for the biobetters market throughout the forecast period.
Want Insights To Biobetters Market? Ask For Sample! https://www.persistencemarketresearch.co/samples/21151
- F.Hoffmann-La Roche AG
- Merck & Co. Inc.
- Sanofi SA
- Porton Biopharma Limited
- Eli Lily and Company
- Novo Nordisk A/S
- Biogen Inc.
- CSL Behring GmbH
- Teva Pharmaceutical Industries Ltd.
Better Therapeutic Outcome at Lower Costs
Moreover, the treatment cost of each cycle using biobetters is relatively lower than that of biologics. For example, Neulasta, a biobetter of Neupogen, costs around US$ 3,400 – 4,000 for each treatment cycle, whereas Neupogen cost around US$ 6,000 at the inception.
Planning To Conclude Your Strategy On A Decisive Note In The Biobetters Market? Glance Through The “Methodology” Implied! https://www.persistencemarketresearch.co/methodology/21151
Although the cost of Neulasta increased considerably, it made only a little difference due to its increased patient compliance and efficacy. However, the market share of Neupogen and its biosimilars remains significantly low, when compared to Neulasta. The superiority of biobetters in terms of pricing, dosage, efficacy, etc. makes them among the most preferred treatment options among patients as well as healthcare professionals.
Various pharmaceutical and biopharmaceutical companies are seeking approval for their respective biobetters for the treatment various diseases. For example, on May 7, 2019, Roche received approval for its Kadcyla drug for the adjuvant treatment of HER2-positive early breast cancer in patients who are affected by residual invasive disease after undergoing neoadjuvant taxane-trastuzumab-based treatment.
Kadcyla was earlier approved for the treatment of HER2-positive metastatic breast cancer. In March 2017, Roche received FDA approval for its drug named Ocrevus (ocrelizumab) for the treatment of the relapsing form of multiple sclerosis.
Pharma and Biopharma Companies Investing in R&D
In terms of revenue, the insulin biobetters segment by drug class in the biobetters market is expected to be a prominent segment over the forecast period. By indication, the biobetters market is expected to be dominated by diabetes over the forecast period due to the higher prevalence of the disease.
By route of administration, the subcutaneous segment of the biobetters market is expected to generate significant revenue during the forecast period due to superior drug delivery as compared to intravenous. By distribution channel, the biobetters market is expected to be dominated by the retail pharmacies segment due to higher patient footfall.
How About Knowing The Product/Technology Driving The Biobetters Market Before Investing Therein? Click The “Purchase Now” Button Of Our Biobetters Market Report! https://www.persistencemarketresearch.com/checkout/21151
North America is expected to be a prominent biobetters market through 2029. Biobetters are approved through the biologics approval pathway as new molecules and hence, they have 10 to 12 years of marketing exclusivity in regions such as North America and Europe, which allows pharmaceutical and biopharmaceutical companies to invest in R&D as it provides assurance to the manufacturers.
The manufacturers of originator biologics tend to develop biobetters of their own product, which allows them to maintain/increase their market share due to the superior qualities of biobetters even after the patent expiry of originator biologics.
For example, Amgen Inc., a manufacturer of Neupogen, launched Aranesp, a drug used for the treatment of anaemia in patients suffering from chronic kidney diseases as well as chemotherapy/radiation-induced myelosuppression in cancer patients.
Access Related Reports:
Hair Transplant Services Market:
According to the research study, the global hair transplant services market is expected to reach a value of over US$ 9,100 Mn by the end of 2025, growing at a CAGR of 6.7% during the forecast period.
Radiology Information Systems:
According to this report, the global market for radiology information systems, which is presently valued at US$ 580.2 Mn, is anticipated to soar at 8.3% CAGR and reach US$ 1,179.2 Mn value by the end of 2024.
Neurosurgical Products Market:
The global neurosurgical products market is predicted to expand at a CAGR of 11.32% for the forecast period between 2017 and 2022, for the market’s valuation of US$4537.2 mn in 2017 to become US$7756.2 mn by the end of 2022.
Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers’ experience by acting as the “missing” link between “customer relationships” and “business outcomes’. The best possible returns are assured therein.
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – [email protected]
Website – https://www.persistencemarketresearch.com
Persistence Market Research Address – 305 Broadway, 7th FloorNew York City, NY 10007 United States U.S. Ph. – +1-646-568-7751 USA-Canada Toll-free – +1 800-961-0353